Shape Therapeutics
Series BTargeted RNA editing and next-generation AAV capsid gene therapy platforms
BiotechnologyTotal Raised: $112M👥 101-250 Employees📍 Seattle, USA
About Shape Therapeutics
Shape Therapeutics uses engineered RNA-guided ADAR deaminase editing enzymes (RNAfix) and synthetic AAV capsids (AAVid) to cure severe genetic neurological diseases without permanent DNA double-strand breaks.
Founders & Leadership
Dr. Francois VigneaultCo-Founder & CEO
Dr. Prashant MaliCo-Founder
Investors & Backers
Funding History
1 roundSimilar Companies in Biotechnology
Explore verified active tech startups operating in the Biotechnology space.